Joshua V. Funder
Direktor/Vorstandsmitglied bei Nuon Therapeutics, Inc.
Profil
Joshua V.
Funder is currently a Director at Opal, Inc. and Nuon Therapeutics, Inc. He previously held positions as CEO at Proacta, Inc., Director at Celladon Corp., Non-Executive Director at Peplin, Inc., Director at Pathway Therapeutics, Inc., Director at Neurovance, Inc., Director at Opal Therapeutics Pty Ltd., Director at Pathway Therapeutics Ltd., Director at Spinifex Pharmaceuticals Pty Ltd., Non-Executive Director at Verva Pharmaceuticals Ltd., Director at Elastagen Pty Ltd., Director at Euthymics Bioscience, Inc., Senior Manager-Corporate Strategy & Development at Infinity Pharmaceuticals, Inc., Partner at GBS Venture Partners Pty Ltd., and Principal at Bill, Hillary & Chelsea Clinton Foundation.
Funder received his undergraduate and graduate degrees from the University of Melbourne, a doctorate from the University of Oxford, and a graduate degree from the London School of Economics & Political Science.
Aktive Positionen von Joshua V. Funder
| Unternehmen | Position | Beginn |
|---|---|---|
Nuon Therapeutics, Inc.
 Nuon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nuon Therapeutics Inc. develops therapies to treat inflammation and neurological diseases. The company focuses on the development and commercialization of new therapies for autoimmune disease and inflammation includes rheumatoid arthritis and multiple sclerosis. Nuon Therapeutics was founded by Kim Puloma Kamdar, Marc Feldmann, Lawrence J. Steinman and Michael Selley in 2006 and is headquartered in San Mateo, CA. | Direktor/Vorstandsmitglied | - |
Opal, Inc.
 Opal, Inc. Electronic Equipment/InstrumentsElectronic Technology Part of Applied Materials, Inc., Opal, Inc. is a private company that makes electronic microscope systems used in manufacturing integrated circuits. The company is based in Santa Clara, CA. Opal was acquired by Orion Corp I on January 10, 1997 for $175 million. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Joshua V. Funder
| Unternehmen | Position | Ende |
|---|---|---|
Proacta, Inc.
 Proacta, Inc. BiotechnologyHealth Technology Proacta, Inc. develops drugs to treat cancer. It is developing a new generation of hypoxia-activated prodrug compounds to treat cancer. The firm’s lead product PR610, is a proprietary, hypoxia-activated prodrug with potential antineoplastic activity. The company was founded in 2001 by William A. Denny, Amato J. Giaccia, William Robert Wilson and Martin J. Brown and is headquartered in La Jolla, CA. | Vorstandsvorsitzender | 01.12.2004 |
| INFINITY PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Euthymics Bioscience, Inc.
 Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | - |
Elastagen Pty Ltd.
 Elastagen Pty Ltd. Medical SpecialtiesHealth Technology Elastagen Pty Ltd. produces and develops synthetic human elastin for medical device applications. Its products include skin rejuvenation, scar remodeling, skin tissue repair, wound healing, surgical glues and sealants. The firm developed a Elastatherapy treatments which offer the chance to restore the levels of Elastin in human skin, with benefits anticipated in both medical dermatology and cosmetic applications. The company was founded by Anthony Weiss in 2003 and is headquartered in Sydney, Australia. | Direktor/Vorstandsmitglied | - |
Bill, Hillary & Chelsea Clinton Foundation
 Bill, Hillary & Chelsea Clinton Foundation Services to the Health IndustryHealth Services Bill, Hillary & Chelsea Clinton Foundation engages in the provision of emergency relief services. It focuses on worldwide issues that demand urgent action, solutions and measurable results - global climate change, Human Immune deficiency/ Acquired Immune Deficiency Syndrome in the developing world, childhood obesity and economic opportunity in the United States and economic development in Africa and Latin America. The company was founded by William Jefferson Clinton in September 2005 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Ausbildung von Joshua V. Funder
| University of Melbourne | Graduate Degree |
| University of Oxford | Doctorate Degree |
| London School of Economics & Political Science | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 16 |
|---|---|
Opal, Inc.
Opal, Inc. Electronic Equipment/InstrumentsElectronic Technology Part of Applied Materials, Inc., Opal, Inc. is a private company that makes electronic microscope systems used in manufacturing integrated circuits. The company is based in Santa Clara, CA. Opal was acquired by Orion Corp I on January 10, 1997 for $175 million. | Electronic Technology |
Proacta, Inc.
Proacta, Inc. BiotechnologyHealth Technology Proacta, Inc. develops drugs to treat cancer. It is developing a new generation of hypoxia-activated prodrug compounds to treat cancer. The firm’s lead product PR610, is a proprietary, hypoxia-activated prodrug with potential antineoplastic activity. The company was founded in 2001 by William A. Denny, Amato J. Giaccia, William Robert Wilson and Martin J. Brown and is headquartered in La Jolla, CA. | Health Technology |
Celladon Corp.
 Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | Health Technology |
Peplin, Inc.
 Peplin, Inc. Pharmaceuticals: MajorHealth Technology Peplin, Inc. develops drugs and pharmaceutical products. The company was founded by James Harrison Aylward in 1998 and is headquartered in Emeryville, CA. | Health Technology |
Pathway Therapeutics, Inc.
 Pathway Therapeutics, Inc. BiotechnologyHealth Technology Pathway Therapeutics, Inc. operates as a clinical stage, privately held, pharmaceutical company developing differentiated and best in class isoform specific PI3-kinase (PI3K) inhibitors for oncology, inflammatory and respiratory diseases. Its lead product include PWT33597, demonstrates excellent in vitro selectivity for its targets, with negligible activity against other protein kinases and other pharmacologically relevant targets at biologically active concentrations. The firm’s other product include PWT143, which has shown outstanding efficacy in in vivo models and has an excellent DMPK and safety profile suitable for advancement in multiple indications. The company was founded in 2010 by William A. Denny and Peter Robin Shepherd and is headquartered in San Francisco, CA. | Health Technology |
Neurovance, Inc.
 Neurovance, Inc. Miscellaneous Commercial ServicesCommercial Services Neurovance, Inc. operates as a a biopharmaceutical company. It develops treatments for central nervous system disorders. The company was founded by Anthony McKinney and Franklin P. Bymaster in 2011 and is headquartered in Cambridge, MA. | Commercial Services |
The Boston Consulting Group, Inc.
 The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | Commercial Services |
GBS Venture Partners Pty Ltd.
 GBS Venture Partners Pty Ltd. Investment ManagersFinance GBS Venture Partners Pty Ltd (GBS Venture Partners) is a venture capital firm founded in 1996 by Helen Brigitte Smith and Geoff E.D Brooke. The firm is headquartered in Melbourne. | Finance |
Opal Therapeutics Pty Ltd.
 Opal Therapeutics Pty Ltd. Pharmaceuticals: MajorHealth Technology Opal Therapeutics Pty Ltd develops immunotherapy for HIV and Hepatitis C & chronic infection. The company was founded in 2005 and is headquartered in Melbourne, Australia. | Health Technology |
Nuon Therapeutics, Inc.
Nuon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nuon Therapeutics Inc. develops therapies to treat inflammation and neurological diseases. The company focuses on the development and commercialization of new therapies for autoimmune disease and inflammation includes rheumatoid arthritis and multiple sclerosis. Nuon Therapeutics was founded by Kim Puloma Kamdar, Marc Feldmann, Lawrence J. Steinman and Michael Selley in 2006 and is headquartered in San Mateo, CA. | Health Technology |
Pathway Therapeutics Ltd.
 Pathway Therapeutics Ltd. Pharmaceuticals: OtherHealth Technology Pathway Therapeutics Ltd. developed drugs for the treatment of cancer. The company was founded in 2007 and was headquartered in Auckland, New Zealand. | Health Technology |
Bill, Hillary & Chelsea Clinton Foundation
Bill, Hillary & Chelsea Clinton Foundation Services to the Health IndustryHealth Services Bill, Hillary & Chelsea Clinton Foundation engages in the provision of emergency relief services. It focuses on worldwide issues that demand urgent action, solutions and measurable results - global climate change, Human Immune deficiency/ Acquired Immune Deficiency Syndrome in the developing world, childhood obesity and economic opportunity in the United States and economic development in Africa and Latin America. The company was founded by William Jefferson Clinton in September 2005 and is headquartered in New York, NY. | Health Services |
Spinifex Pharmaceuticals Pty Ltd.
 Spinifex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology Spinifex Pharmaceuticals Pty Ltd. discovers and develops new drugs for the treatment and management of pain. The firm conducts medicinal chemistry and drug discovery activities, preclinical and early-phase clinical studies before seeking a partnership with pharmaceutical company to complete clinical development, file for regulatory approval, and carry out marketing activities. The company was founded in June 2005 and is headquartered in Preston, Australia. | Health Technology |
Verva Pharmaceuticals Ltd.
 Verva Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Verva Pharmaceuticals Ltd. developed therapies to treat diabetes. Its products include insulin sensitizers, insulin secretagogues, fat formation inhibitors for the prevention, treament of obesity, drug-induced weight gain and insulin secretion modulators. The company was founded in 1996 and was headquartered in Geelong, Australia. | Health Technology |
Elastagen Pty Ltd.
Elastagen Pty Ltd. Medical SpecialtiesHealth Technology Elastagen Pty Ltd. produces and develops synthetic human elastin for medical device applications. Its products include skin rejuvenation, scar remodeling, skin tissue repair, wound healing, surgical glues and sealants. The firm developed a Elastatherapy treatments which offer the chance to restore the levels of Elastin in human skin, with benefits anticipated in both medical dermatology and cosmetic applications. The company was founded by Anthony Weiss in 2003 and is headquartered in Sydney, Australia. | Health Technology |
Euthymics Bioscience, Inc.
Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA. | Commercial Services |
